Analysis of Upper Gastrointestinal Hemorrhage Cases after Percutaneous Coronary Intervention

Abstract

Abstract: Objective To analyze upper gastrointestinal hemorrhage cases after coronary angiography and/or percuta-neous coronary intervention. Methods We retrospectively evaluated the clinical information of 33 524 patients un-dergoing coronary angiography and/or percutaneons coronary intervention in our hospital from January 2007 to December 2009, 42 patients with upper gastrointestinal hemorrhage, were analyzed. Results The majority of upper gastrointestinal bleeding occurred in percutaneous coronary intervention within 48 hours after treatment, mostly for a small amount of bleeding and in the patients with muti-vessel disease, and more men than women. Conclusion Upper gastrointestinal bleeding after percutaneous coronary intervention were caused by a variety of reasons. In the application process, identification and treatment for upper gastrointestinal hemorrhage should be strengthened.

Key words: percutaneous coronary intervention, upper gastrointestinal hemorrhage, analysis

CLC Number:

R972.7

XIE Shuang, XU Bo, YANG Yue-jin, LOU Ying, LI Yi-shi. Analysis of Upper Gastrointestinal Hemorrhage Cases after Percutaneous Coronary Intervention[J]. Chinese Journal of Pharmacovigilance, 2010, 7(5): 277-280.

References

[1] 陈灏珠,李宗明主编. 内科学[M]. 3版. 北京：人民卫生出版社 1995：428-434.
[2] 姚希贤.临床消化病学[M].天津：天津科学技术出版社,1999：498.
[3] Grines C L, Bonow R O, Casey D E, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents[J]. Circulation, 2007,115:813-818.
[4] Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study[J].BMJ, 2006,333:726-730.
[5] Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on use of antiplatelet agents[J]. Eur Heart J, 2004, 25:166-181.
[6] CAPRIE Investigators. A randomized, blinded trial of clopidogrel versus asprin in patients at risk of ischeamic events[J]. Lancet, 1996,348:1329-1339.
[7] Ng F H, Wong S Y, Chang C M, et al. High incidence of cloidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease[J].Aliment Pharmacol Ther, 2003,18:443-449.
[8] Yusuf S, Zhao F, Mehta S R, et al. Effect of colpidogrel in addition to asprin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med, 2001,345:494-502.
[9] Joseph A D, Lucie O, James M B, et al. Drug-drug interaction between antithrombotic medications and the risk of gastrointestinal bleeding[J]. CMAJ,2007,177(4):347-351.
[10] Eikelboom J W, Hirsh J. Bleeding and management of bleeding[J]. Eur Heart J, 2006,8:G38-45.
[11] CURE Trial Investigators. Effects of aspirin dose when used alone or in combination with colpidogrel in patients with acute coronary syndromes[J]. Circulation, 2003,108:1682-1687.
[12] 王世安,孟克,张新民,等.奥美拉唑预防高危患者术后应激性溃疡的体会[J].中华现代外科学杂志,2009,6：363-364.
[13] 彭风芹,郭洪涛,苗青,等.洛赛克与雷尼替丁预防冠心病PTCA+STENT术后并发上消化道出血的临床研究[J].现代中西医结合杂志,2003,12:1482-1484.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[3]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[4]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[5]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[6]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[7]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[8]	ZHANG Lei, LYU Jian, XIE Yanming. Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
[9]	LIU Jingjing, DAI Zhong, YANG Jianbo, WANG Ying, XU Beilei, LIU Yue, WANG Qi, MA Shuangcheng. Spectrum-fect relationship of Ginseng Radix et Rhizoma Rubra and Polygonum Multiflorum Radix Preparata medicinal pair in protection of nerve cells [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 623-628.
[10]	CHEN Xiao, GUO Xiaojing, XU Jinfang, WEI Lianhui, CHEN Chenxin, LIANG Jizhou, ZHENG Yi, YE Xiaofei. Machine learning method in the detection of adverse drug reaction signals of brigatinib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 639-645.
[11]	ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei. Discuss the safety management of medical toxic drugs in medical institutions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
[12]	LIU Baosheng, WANG Guanjie, WANG Zhenhua, LIU Lihong, ZHU Yan, ZHOU Xiuli. One case of acute liver injury caused by tripterygium glycosides tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 511-513.
[13]	CHENG Fengjingming, LYU Jian, XIE Yanming. Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
[14]	WANG Guohua, LI Xiaolei, LIU Xiping, DONG Yizhi, ZANG Chen, XU Hong, TIAN Jixiang, ZHAO Jing. Aerosol inhalation of Tanreqing injection in the treatment of chronic obstructive pulmonary disease: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 544-552.
[15]	XU Shuai, CHEN Xun, BIAN Haoyu, ZHAO Yuqing, ZHANG Liping. Research hotspots and trends of herb-induced liver injury based on CiteSpace knowledge maps [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 560-567.